Pelabresib (CPI-0610), an oral bromodomain and extra-terminal domain (BET) inhibitor, represents a promising therapeutic advancement for myelofibrosis (MF), a myeloproliferative neoplasm driven by JAK-STAT pathway dysregulation and characterized by bone marrow fibrosis, cytopenias, and systemic inflammation [121] (Table 1). Here, SOAT1 is linked to myeloproliferative neoplasm.